Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Company Profile

Previous Hold Today ACST ranks #2557 as HOLD CANDIDATE #2557 Next Hold

ACST stock forecast Acasti Pharma

ACST stock forecast

Acasti Pharma

545 Promenade du Centropolis

Laval, QC H7T 0A3


Industry: Biotechnology

Sector: Healthcare


Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of various cardiometabolic disorders primarily abnormalities in blood lipids. The company offers Onemia, a medical food product for the dietary management of omega-3 phospholipids deficiency, and related abnormal lipid profiles and cardiometabolic disorders. It also develops CaPre, a prescription drug candidate for the prevention and treatment of cardiometabolic disorders, such as hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies and Bioressources Inc.

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank